


*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 590558

INFORMATION DISCLOSURE CITATION PTO-1449				ATTY. DOCKET NO. P1134R2		SERIAL NO. 09/157,289		
				APPLICANTS Ashkenazi et al.				
				FILING DATE September 18, 1998		GROUP 1646		
U.S. PATENT DOCUMENTS								
EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
<i>cu</i>		5,885,800	3/23/99	Emery et al.				
								
FOREIGN PATENT DOCUMENTS								
EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							Yes	No
<i>cu</i>		19,809,978.	9/16/99	Germany			<input checked="" type="checkbox"/>	<input type="checkbox"/>
<i>cu</i>		99/11791	3/11/99	PCT (WO)			<input checked="" type="checkbox"/>	<input type="checkbox"/>
<i>cu</i>		99/31128	6/24/99	PCT (WO)			<input checked="" type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
EXAMINER <i>Plan M. L.</i>		DATE CONSIDERED <i>2/6/01</i>						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 590558

FORM PTO-1449				U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1134R2	Serial No. 09/157,289
LIST OF DISCLOSURES CITED BY APPLICANT				Oct 06 2000	Applicant Ashkenazi et al.	
(Use several sheets if necessary)					Filing Date 18 Sep 1998	Group 1646

U.S. PATENT DOCUMENTS


Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
<i>CW</i>	1	60/079,856		Dou et al.			30.03.98
	2	60/086,074		Dou et al.			20.05.98
	3	60/099,643		Dou et al.			09.09.98
	4	60/112,577		Dou et al.			17.12.98
	5	60/112,703		Dou et al.			18.12.98
	6	60/112,933		Dou et al.			18.12.98
	7	60/113,407		Dou et al.			22.12.98

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
<i>CW</i>	8	WO 00/32221	08.06.00	PCT			
<i>CW</i>	9	WO 00/53758	14.09.00	PCT			

Examiner	<i>Clare M. Kay</i>	Date Considered <i>2/6/01</i>
----------	---------------------	----------------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FILE COPY

Sheet 1 of 9

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.
11669.31US03

Serial No.
09/157,289

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Ashkenazi et al.

Filing Date
18 Sep 1998

Group
1646

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
<i>CCL</i>	1	4,179,337	18.12.79	Davis et al.			
	2	4,301,144	17.11.81	Iwashita et al.			
	3	4,399,216	16.08.83	Axel et al.			
	4	4,496,689	29.01.85	Mitra, G.			
	5	4,640,835	03.02.87	Shimizu et al.			
	6	4,670,417	02.06.87	Iwasaki et al.			
	7	4,676,980	30.06.87	Segal et al.			
	8	4,736,866	12.04.88	Leder et al.			
	9	4,791,192	13.12.88	Nakagawa et al.			
	10	4,816,567	28.03.89	Cabilly et al.			
	11	4,870,009	26.09.89	Evans et al.			
	12	5,010,182	23.04.91	Brake et al.			
	13	5,364,934	15.11.94	Drayna et al.			
	14	5,447,851	05.09.95	Beutler et al.			
	15	607035-496					14.01.97
	16	60/035,722					28.01.97
<i>Cem</i>	17	60/037,829		DO NOT PRINT			05.02.97

FOREIGN PATENT DOCUMENTS


Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
<i>CCL</i>	18	003,089	25.07.79	EPO (ENGLISH ABSTRACT ATTACHED)				
	19	036,776	30.09.81	EPO				
	20	073,657	09.03.83	EPO				
	21	117,058	29.08.84	EPO				
	22	117,060	29.08.84	EPO				
	23	307,247	15.03.89	EPO				
	24	362,179	04.04.90	EPO				
	25	417,563	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)				
<i>Cem</i>	26	861,850	02.09.98	EPO				
<i>Cem</i>	27	WO 87/05330	11.09.87	PCT				
<i>Cem</i>	28	WO 89/05859	29.06.89	PCT				
<i>Cem</i>	29	WO 90/13646	15.11.90	PCT				
<i>Cem</i>	30	WO 91/00360	10.01.91	PCT				
<i>Cem</i>	31	WO 92/20373	26.11.92	PCT				
<i>Cem</i>	32	WO 93/08829	13.05.93	PCT				
<i>Cem</i>	33	WO 97/23614	03.07.97	PCT				

Examiner *CCL*

Date Considered

2/6/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
11669.31US03Serial No.
09/157,289Applicant
Ashkenazi et al.Filing Date
18 Sep 1998Group
1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
CW	34	WO 97/25428	17.07.97	PCT				
Cl	35	WO 98/30694	16.07.98	PCT				
CW	36	WO 98/32856	30.07.98	PCT				
Cl	37	GB 2,211,504	05.07.89	UNITED KINGDOM				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	* 38	Mammalian Cell Biotechnology: A Practical Approach, M. Butler, ed., IRL Press (1991)
	* 39	Remington's Pharmaceutical Sciences, Oslo et al., eds., 16th edition, Mack Publishing Co. (1980)
	* 40	Chemotherapy Service Ed., M.C. Perry, Baltimore, MD:Williams & Wilkins (1992)
CW	41	Handbook of Monoclonal Antibodies, Ferrone et al. eds., Park Ridge, NJ:Noyes Publications, pps. 302-359 and Chapter 22 (1985)
	42	Altschul et al., "Local alignment statistics" Methods in Enzymology 266:460-480 (1996)
	43	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-induced Death of Developing T Cells" Cold Spring Harbor Laboratory Symposium on Programmed Cell Death (Abstr. No. 10) (1995)
	44	Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function" Nature 390(6656):175-179 (Nov 13, 1997)
	45	Anderson, W.F., "Human gene therapy" Science 256:808-813 (1992)
	46	Aplin et al., "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids" CRC Crit. Rev. Biochem. 10(4):259-306 (1981)
	47	Arase et al., "Fas-mediated cytotoxicity by freshly isolated natural killer cells" Journal of Experimental Medicine 181(3):1235-1238 (Mar 1, 1995)
	48	Ashkenazi and Chamow, "Immunoadhesins: An Alternative to Human Monoclonal Antibodies" Methods: A Companion to Methods in Enzymology 8:104-115 (1995)
	49	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" Proc. Natl. Acad. Sci. 88:10535-10539 (1991)
	50	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation" Cell 73:431-445 (1993)
	51	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" Immunity 6:79-88 (1997)
	52	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" The Journal of Immunology 147(1):86-95 (1991)
CW	53	Bolivar et al., "Construction and Characterization of New Cloning Vehicles. II. A Multipurpose Cloning System" Gene 2:95-113 (1977)

Examiner


Ch. M. Key

Date Considered

2/6/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No. 11669.31US03	Serial No. 09/157,289
Applicant Ashkenazi et al.	
Filing Date 18 Sep 1998	Group 1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Cl	54	Bradley, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987)
	55	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
	56	Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 51-63 (1987)
	57	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (Nov 29, 1996)
	58	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (1985)
	59	Chang et al., "Phenotypic Expression in E. coli of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" <u>Nature</u> 275:617-624 (October 19, 1978)
	60	Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis" <u>Journal of Biological Chemistry</u> 272(51):32401-32410 (Dec 19, 1997)
	61	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)
Cl	62	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-14 (1976)
Cl	63	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , Reisfeld et al., New York:Alan R. Liss, Inc. pps. 77-96 (1985)
	64	Coligan et al. <u>Current protocols in immunology</u> , New York:John Wiley & Sons (1994)
Cl	65	Creighton, "Protein Biosynthesis" <u>Proteins: Structures and Molecular Principles</u> , San Francisco:W.H. Freeman & Co. pps. 79-86 (1983)
	66	David et al., "Protein Iodination with Solid State Lactoperoxidase" <u>Biochemistry</u> 13(5):1014-1021 (1974)
	67	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon-γ" <u>European Journal of Immunology</u> 17:689-693 (1987)
	68	deBoer et al., "The TAC Promoter: A functional Hybrid Derived From the TRP and LAC Promoters" <u>Proc. Natl. Acad. Sci. USA</u> 80:21-25 (1983)
	69	Deutscher, M., "Rethinking your purification procedure" <u>Methods in Enzymology</u> 182:779-780 (1990)
Cl	70	Dhein et al., "Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)" <u>Nature</u> 373(6513):438-441 (Feb 2, 1995)
	71	Dieffenbach et al., <u>PCR Primer: A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press (1995)
Cl	72	Dzau et al., "Gene therapy for cardiovascular disease" <u>Trends in Biotechnology</u> 11:205-210 (1993)
Cl	73	Edge et al., "Deglycosylation of glycoproteins by trifluoromethanesulfonic acid" <u>Analytical Biochemistry</u> 118:131-137 (1981)

Examiner

Clay M. Key

Date Considered

2/6/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. 11669.31US03	Serial No. 09/157,289
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)			Applicant Ashkenazi et al.	
			Filing Date 18 Sep 1998	Group 1646
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
<i>Cler</i>	74	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular & Cellular Biology</u> 5:3610-3616 (1985)		
	75	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <u>Saccharomyces cerevisiae</u> by Use of an Epitope Addition Method" <u>Molecular & Cellular Biology</u> 8:2159-2165 (1988)		
	76	Gelb et al., "Pycnodysostosis: Refined Linkage and Radiation Hybrid Analyses Reduce the Critical Region to 2 cM at 1q21 and Map Two Candidate Genes" <u>Human Genet.</u> 98:141-144 (1996)		
	77	Gelmini et al., "Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification" <u>Clinical Chemistry</u> 43(5):752-758 (May 1997)		
	78	Gething et al., "Cell-surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene" <u>Nature</u> 293:620-625 (October 22, 1981)		
	79	Goding, "Production of Monoclonal Antibodies" <u>Monoclonal Antibodies: Principles and Practice</u> , Academic Press, pps. 59-103 (1986)		
	80	Goeddel et al., "Direct Expression in <u>Escherichia coli</u> of a DNA Sequence Coding for Human Growth Hormone" <u>Nature</u> 281:544-548 (October 18, 1979)		
	81	Goeddel et al., "Synthesis of Human Fibroblast Interferon by <u>E. coli</u> " <u>Nucleic Acids Research</u> 8(18):4057-4074 (1980)		
	82	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular & Cellular Biology</u> 11:3020-3026 (1991)		
	83	Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <u>J. Gen. Virol.</u> 36:59-72 (1977)		
	84	Graham et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" <u>Virology</u> 52:456-467 (1973)		
	85	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)		
	86	Hahne et al., "Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape" <u>Science</u> 274(5291):1363-1366 (Nov 22, 1996)		
	87	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in <u>E. coli</u> " <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)		
	88	Hess et al., "Cooperation of Glycolytic Enzymes" <u>Advances in Enzyme Regulation</u> , George Weber, New York:Pergamon Press Vol. 7:149-167 (1968)		
	89	Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique" <u>Journal of Biological Chemistry</u> 255(24):12073-12080 (December 25, 1980)		
	90	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF α)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)		
	91	Holland et al., "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase" <u>Biochemistry</u> 17(23):4900-4907 (1978)		
	92	Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" <u>Science</u> 253(5025):1278-1280 (Sep 13, 1991)		
<i>Cler</i>	93	Hoogenboom and Winter, "By-passing immunisation: human antibodies from synthetic repertoires of germline V κ gene segments rearranged in vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)		
Examiner <i>Clare M. [Signature]</i>		Date Considered <i>2/6/01</i>		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. 11669.31US03	Serial No. 09/157,289
LIST OF DISCLOSURES CITED BY APPLICANT & TRADEMARK OFFICE				Applicant Ashkenazi et al.	
(Use several sheets if necessary)				Filing Date 18 Sep 1998	Group 1646
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
<i>Cen</i>	94	Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" <u>Bio/Technology</u> 6:1204-1210 (1988)			
	95	Hsiao et al., "High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg4 Gene" <u>Proc. Natl. Acad. Sci. USA</u> 76:3829-3833 (1979)			
	96	Hunter et al., "Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity" <u>Nature</u> 194:495-496 (1962)			
	97	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)			
	98	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (November 21, 1986)			
	99	Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)			
	100	Jones, E., "Proteinase Mutants of <i>Saccharomyces Cerevisiae</i> " <u>Genetics</u> 85(1):23-33 (1977)			
	101	Keown et al., "Methods for Introducing DNA into Mammalian Cells" <u>Methods in Enzymology</u> 185:527-537 (1990)			
	102	Kingsman et al., "Replication in <i>Saccharomyces Cerevisiae</i> of Plasmid pBR313 Carrying DNA from the Yeast trp1 Region" <u>Gene</u> 7:141-152 (1979)			
	103	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)			
	104	Kohler et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)			
	105	Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)			
	106	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" <u>The Journal of Immunology</u> 133(6):3001-3005 (1984)			
	107	Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)			
	108	Kwon et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer" <u>Proc. Natl. Acad. Sci. USA</u> 94(15):8099-8103 (Jul 22, 1997)			
	109	Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation" <u>Cell</u> 93(2):165-176 (Apr 17, 1998)			
	110	Leach et al., "Enhancement of antitumor immunity by CTLA-4 blockade" <u>Science</u> 271(5256):1734-1736 (Mar 22, 1996)			
	111	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)			
	112	Li et al., "Targeted mutation of the DNA methyltransferase gene results in embryonic lethality" <u>Cell</u> 69:915-926 (1992)			
<i>Cen</i>	113	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (April 20, 1990)			
Examiner <i>Chris M. K.</i>			Date Considered <i>2/6/01</i>		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce

Patent and Trademark Office

APR 12 1998

SEARCHED

INDEXED

MAILED

TRADEMAKES

Atty Docket No.

11669.31US03

Serial No.

09/157,289

Applicant

Ashkenazi et al.

Filing Date

18 Sep 1998

Group

1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

114	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990)
115	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)
116	Mansour et al., "Disruption of the Proto-oncogene int-2 in Mouse Embryo-derived Stem Cells: a General Strategy for Targeting Mutations to Non-selectable Genes" <u>Nature</u> 336:348-352 (1988)
117	Mantei et al., "Rabbit β-globin mRNA Production in Mouse L Cells Transformed with Cloned Rabbit β-globin Chromosomal DNA" <u>Nature</u> 281:40-46 (September 6, 1979)
118	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
119	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)
120	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF-κB" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
121	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF-κB and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14032 (1997)
122	Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3" <u>Current Biology</u> 8(9):525-528 (Apr 23, 1998)
123	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K ⁺ Channel Currents" <u>Science</u> 255:192-194 (1992)
124	Mather et al., "Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines" <u>Biol. Reprod.</u> 23:243-252 (1980)
125	Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator" <u>Immunity</u> 8(1):21-30 (Jan 1998)
126	Medvedev et al., "Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas- ligand in NK/LAK cell-mediated cytotoxicity" <u>Cytokine</u> 9(6):394-404 (Jun 1997)
127	Merrifield, R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" <u>J. Am. Chem. Soc.</u> 85:2149-2154 (1963)
128	Milstein et al., "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (1983)
129	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)
130	Moretta, A., "Molecular mechanisms in cell-mediated cytotoxicity" <u>Cell</u> 90(1):13-18 (Jul 11, 1997)
131	Munson et al., "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" <u>Analytical Biochemistry</u> 107:220-239 (1980)
132	Nagata, "Apoptosis by Death Factor" <u>Cell</u> 88:355-365 (1997)
133	Nagata et al., "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)

Examiner

Chris N. G.

Date Considered

3/6/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. 11669.31US03	Serial No. 09/157,289
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.	
				Filing Date 18 Sep 1998	Group 1646
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
<i>Ch</i>	134	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990)			
<i>Ch</i>	135	Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>The Journal of Histochemistry and Cytochemistry</u> 30(5):407-412 (1982)			
	*136	<u>O'Reilly, D. Baculovirus expression vectors: a laboratory manual</u> , New York:Oxford University Press (1994)			
<i>Ch</i>	137	Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" <u>Protein Eng.</u> 3(6):547-553 (1990)			
	138	Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" <u>Journal of Immunological Methods</u> 40:219-230 (1981)			
	139	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)			
	140	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)			
	141	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>Eur. J. Haematol.</u> 41:414-419 (1988)			
	142	Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" <u>Nature</u> 312:724-729 (1984)			
	143	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)			
	144	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)			
	145	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (February 12, 1987)			
	146	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (March 24, 1988)			
<i>Ch</i>	147	Ruppert et al., "Cloning and Expression of Human TAF11250: a TBP-associated Factor Implicated in Cell-cycle Regulation" <u>Nature</u> 362:175-179 (1993)			
	*148	<u>Sambrook et al. Molecular Cloning: A Laboratory Manual</u> , Second edition, New York:Cold Spring Harbor Laboratory Press (1989)			
	*149	<u>Samter et al. Samter's Immunological Diseases</u> , 5th edition, Boston:Little, Brown and Company Vol. I & II ("1995")			
<i>Ch</i>	150	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (April 20, 1990)			
<i>Ch</i>	151	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" <u>Proc. Natl. Acad. Sci. USA</u> 83:1881-1885 (1986)			
	*152	<u>Scopes, R. Protein Purification</u> , New York:Springer-Verlag (1982)			
<i>Ch</i>	153	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor α Inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989)			
Examiner <i>Ch - M. K</i>				Date Considered <i>2/6/01</i>	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. 11669.31US03	Serial No. 09/157,289
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)			Applicant Ashkenazi et al.	
			Filing Date 18 Sep 1998	Group 1646

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

<i>Au</i>	154	Shaw et al., "A General Method for the Transfer of Cloned Genes to Plant Cells" <u>Gene</u> 23:315-330 (1983)
	155	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
	156	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (Apr 18, 1997)
	157	Skinner et al., "Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins" <u>Journal of Biological Chemistry</u> 266:14163-14166 (1991)
	158	Smith et al., "Cardiac Glycoside-Specific Antibodies in the Treatment of Digitalis Intoxication" <u>Antibodies in Human Diagnosis and Therapy</u> pps. 365-389 (1977)
	159	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (May 25, 1990)
	160	Smith et al., "T2 Open reading frame from the shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. & Biophys. Res. Comm.</u> 176:335-342 (1991)
	161	Sojar et al., "A Chemical Method for the Deglycosylation of Proteins" <u>Archives of Biochemistry & Biophysics</u> 259(1):52-57 (1987)
	162	Sompayrac et al., "Efficient infection of monkey cells with DNA of simian virus 40" <u>Proc. Natl. Acad. Sci. USA</u> 78(12):7575-7578 (Dec 1981)
<i>Av</i>	163	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989)
	*164	<u>Stewart et al. Solid-Phase Peptide Synthesis</u> , San Francisco, CA:W.H. Freeman Co. (1969)
<i>Cn</i>	165	Stinchcomb et al., "Isolation and Characterisation of a Yeast Chromosomal Replicator" <u>Nature</u> 282:39-43 (November 1, 1979)
	166	Strand et al., "Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells --a mechanism of immune evasion?" <u>Nature Medicine</u> 2(12):1361-1366 (Dec 1996)
	167	Suda et al., "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family" <u>Cell</u> 75:1169-1178 (1993)
	168	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)
	169	Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993)
	170	Thimmappaya et al., "Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection" <u>Cell</u> 31(3 Pt 2):543-551 (Dec 1982)
	171	Thomas et al., "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" <u>Cell</u> 51:503-512 (1987)
	172	Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5201-5205 (September 1980)
<i>Cn</i>	173	Thotakura et al., "Enzymatic Deglycosylation of Glycoproteins" <u>Meth. Enzymol.</u> 138:350-359 (1987)

Examiner

Chris M. Karp

Date Considered

2/6/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. 11669.31US03	Serial No. 09/157,289
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)			Applicant Ashkenazi et al.	
			Filing Date 18 Sep 1998	Group 1646
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
<i>CW</i>	174	Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" <u>EMBO Journal</u> 10(12):3655-3659 (1991)		
	175	Tschumper et al., "Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene" <u>Gene</u> 10:157-166 (1980)		
	176	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)		
	177	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the shope fibroma virus genome" <u>Virology</u> 160:20-29 (1987)		
	178	Urlaub et al., "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> 77(7):4216-4220 (July 1980)		
	179	Van Solingen et al., "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> 130:946-947 (1977)		
	180	Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)		
	181	Wagner et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells" <u>Proc. Natl. Acad. Sci.</u> 87:3410-3414 (1990)		
	182	Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" <u>Proc. Natl. Acad. Sci. USA</u> 88:159-163 (1991)		
	183	Wells et al., "Cassette Mutagenesis: an Efficient Method for Generation of Multiple Mutations at Defined Sites" <u>Gene</u> 34(2-3):315-323 (1985)		
	184	Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" <u>Philos. Trans. R. Soc. London Ser A</u> 317:415-423 (1986)		
	185	Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995)		
	186	Wong et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells" <u>Journal of Biological Chemistry</u> 272(40):25190-25194 (Oct 3, 1997)		
	187	Wu et al., "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system" <u>Journal of Biological Chemistry</u> 262(10):4429-4432 (1987)		
	188	Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" <u>Journal of Biological Chemistry</u> 266:12099-12104 (1991)		
	189	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989)		
	190	Zamecnik et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA" <u>Proc. Natl. Acad. Sci.</u> 83:4143-4146 (1986)		
	191	Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" <u>Nature</u> 377:348-351 (1995)		
	192	Zola, "Using Monoclonal Antibodies: Soluble Antigens" <u>Monoclonal Antibodies: A Manual of Techniques</u> , CRC Press, Chapter 6, pps. 147-158 (1987)		
<i>CW</i>	193	Zoller et al., "Oligonucleotide-directed Mutagenesis Using M13-derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" <u>Nucl. Acids Res.</u> 10(20):6487-6500 (1982)		
Examiner <i>Ch. M. K.</i>			Date Considered <i>2/6/01</i>	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				